Qualitative Analysis Of The Treatment Experience And Well-Being Of Patients With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (Lbcl) Enrolled In 2 Trials Of Lisocabtagene Maraleucel (Liso-Cel) During The Initial Stages Of Therapy

Background: Chimeric antigen receptor (CAR) T cell therapy is a novel treatment modality for patients with R/R LBCL. Limited information exists regarding patients' views of CAR T cell therapy. Our research aimed to better understand patients' needs by capturing their expectations/concerns, current well-being, and treatment experiences during the beginning stages of CAR T cell therapy in the clinical trial setting.